1. Medtech Insight

VolitionRx Gets Green Light For Nucleosome-Based Colorectal Cancer Test

 
• By Catherine Longworth

Blood-based cancer diagnostics firm VolitionRx CE-marked a new colorectal cancer-screening test that has shown the potential to reduce unnecessary colonoscopies by up to 25% when combined with the fecal immunochemical test (FIT) score.

Blood-based cancer diagnostics firm VolitionRx Ltd. has launched a new colorectal cancer blood-screening test for use with fecal immunochemical tests (FITs).

Nu.Q is an ELISA test based on technology that detects colorectal cancer by identifying related nucleosomes in the bloodstream. Nucleosomes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

More from Device Area